Powered by

BIOPHYTIS completes a ‚¬10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates

PARIS, Oct. 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, announces entry into definitive agreements for a ‚¬ 10.4 million capital raise via the issuance of new ordinary shares without shareholders' preferential subscription rights and reserved to institutional investors in Europe and the United States.

Stanislas Veillet, Chairman and Chief Executive Office

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox